Eliapixant

Eliapixant (BAY 1817080) is a potent and selective antagonist of P2X3 receptor, with an IC50 of 8 nM. Eliapixant can be used for the research of refractory chronic cough[1][2].

Product Specifications

CAS Number

[1948229-21-7]

Product Name Alternative

BAY 1817080

UNSPSC

12352005

Target

P2X Receptor

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/eliapixant.html

Purity

99.95

Solubility

DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C[C@H](C1=CN=C(C(F)(F)F)N=C1)NC(C2=CC(O[C@@H]3CCOC3)=CC(C4=NC=C(S4)C)=C2)=O

Molecular Formula

C22H21F3N4O3S

Molecular Weight

478.49

References & Citations

[1]Morice A, et, al. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240.|[2]Spinaci A, et, al. P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications. Front Pharmacol. 2021 Apr 13;12:653561.